Status:
COMPLETED
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
Lead Sponsor:
Pfizer
Conditions:
Vasomotor Symptoms
Eligibility:
FEMALE
45+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in meno...
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women who seek treatment for hot flushes
- Body Mass Index (BMI) less than or equal to 34 kg/m\^2
Exclusion
- Hypersensitivity to Venlafaxine
- Myocardial infarction an/or unstable angina within 6 months of screening
- History of seizure disorder
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
2186 Patients enrolled
Trial Details
Trial ID
NCT00683800
Start Date
June 1 2008
End Date
May 1 2010
Last Update
August 17 2011
Active Locations (121)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35235
2
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
3
Pfizer Investigational Site
Montgomery, Alabama, United States, 36106
4
Pfizer Investigational Site
Glendale, Arizona, United States, 85308